Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul;126(1):10-19.
doi: 10.1002/jso.26812.

Cancer risk-reducing surgery: Brazilian society of surgical oncology guideline part 1 (gynecology and breast)

Vandré Cabral Gomes Carneiro  1   2   3 , Ana Carolina Leite Vieira Costa Gifoni  3 , Benedito Mauro Rossi  4 , Carlos Eduardo Mattos da Cunha Andrade  5 , Fernanda Teresa de Lima  6   7 , Henrique de Campos Reis Galvão  8 , Jose Claudio Casali da Rocha  9 , Leonardo Silveira da Silva Barreto  10 , Patrícia Ashton-Prolla  11 , Rodrigo Santa Cruz Guindalini  3 , Terence Pires de Farias  12 , Wesley Pereira Andrade  13   14   15 , Paulo Henrique de Sousa Fernandes  16 , Reitan Ribeiro  17 , Andre Lopes  18 , Audrey Tieko Tsunoda  17   19 , Bruno Roberto Braga Azevedo  20   21 , Carlos Augusto Martinez Marins  12   22 , Diego Nunes de Albuquerque Oliveira Uchôa  23 , Evandro Airton Sordi Dos Santos  24 , Felipe José Fernández Coimbra  9 , Francisco Alcides Dias Filho  25 , Francisco Carlos de Oliveira Lopes  26 , Francisco Guilherme Fernandes  27 , Guilherme Fonteles Ritt  28 , Gustavo Andreazza Laporte  29 , Gustavo Cardoso Guimaraes  13 , Heládio Feitosa E Castro Neto  30 , Jocela Cristina Dos Santos  31 , Jordana Botelho de Carvalho Vilela  32 , Jorge Guardiola Meinhardt Junior  29   33 , Juliano Rodrigues da Cunha  16 , Leonardo Medeiros Milhomem  34 , Luciana Mata da Silva  2 , Luiza de Freitas Maciel  12 , Nathalia Moreira Ramalho  1   3 , Rafael Leite Nunes  35 , Rodrigo Guido de Araújo  2 , Rogério de Assunção Ehrhardt  2 , Ronald Enrique Delgado Bocanegra  36 , Tyrone Cesar Silva Junior  37 , Viviane Rezende de Oliveira  38 , Walyson Silva Surimã  39 , Miriam de Melo Melquiades  40 , Heber Salvador de Castro Ribeiro  9   41 , Alexandre Ferreira Oliveira  42   43
Affiliations

Cancer risk-reducing surgery: Brazilian society of surgical oncology guideline part 1 (gynecology and breast)

Vandré Cabral Gomes Carneiro et al. J Surg Oncol. 2022 Jul.

Abstract

Background: Risk-reducing operations are an important part of the management of hereditary predisposition to cancer. In selected cases, they can considerably reduce the morbidity and mortality associated with cancer in this population.

Objectives: The Brazilian Society of Surgical Oncology (BSSO) developed this guideline to establish national benchmarks for cancer risk-reducing operations.

Methods: The guideline was prepared from May to December 2021 by a multidisciplinary team of experts to discuss the surgical management of cancer predisposition syndromes. Fourteen questions were defined and assigned to expert groups that reviewed the literature and drafted preliminary recommendations. Following a review by the coordinators and a second review by all participants, the groups made final adjustments, classified the level of evidence, and voted on the recommendations.

Results: For all questions including risk-reduction bilateral salpingo-oophorectomy, hysterectomy, and mastectomy, major agreement was achieved by the participants, always using accessible alternatives.

Conclusion: This and its accompanying article represent the first guideline in cancer risk reduction surgery developed by the BSSO, and it should serve as an important reference for the management of families with cancer predisposition.

Keywords: breast cancer; cancer risk-reducing; ovarian cancer; practice guideline; surgery.

PubMed Disclaimer

References

REFERENCE

    1. Moore K, Colombo N, Scambia G, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379:2495-2505.
    1. Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med. 2017;377:523-533.
    1. Litton JK, Rugo HS, Ettl J, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379:753-763.
    1. de Bono J, Mateo J, Fizazi K, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382:2091-2102.
    1. Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA-mutated metastatic 2201 pancreatic cancer. N Engl J Med. 2019;381:317-327.

LinkOut - more resources